Semaglutide oral - Novo Nordisk

Drug Profile

Semaglutide oral - Novo Nordisk

Alternative Names: GLP-1-SNAC; NN-9924; NNC0113-0217; OG-217SC

Latest Information Update: 14 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Novo Nordisk
  • Class Antihyperglycaemics; Glucagon-like peptides
  • Mechanism of Action Glucagon like peptide 1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Type 2 diabetes mellitus

Highest Development Phases

  • Phase III Type 2 diabetes mellitus

Most Recent Events

  • 26 Oct 2018 Efficacy and adverse events data from the phase 3a PIONEER 8 trial in Type-2 diabetes released by Novo Nordisk
  • 19 Oct 2018 Novo Nordisk completes a phase I trial for Type-2 diabetes mellitus in United Kingdom (PO) (NCT02773381)
  • 01 Oct 2018 Adverse events and efficacy data from the phase III PIONEER 1 trial in Type-2 diabetes mellitus presented at the 54th Annual Meeting of the European Association for the Study of Diabetes (EASD-2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top